Press Releases

NASDAQ
SPPI
$10.56
--0.35
DAY HI:
$10.90
DAY LOW:
$10.43
VOLUME:
627,759
2:59 PM EST 01/22/19

Press Releases

Date Title View PDF
Jan 17, 2019 Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma L.L.C. to Focus on New and Innovative Therapies for Cancer Patients
Jan 2, 2019 Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations
Dec 27, 2018 Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
Dec 19, 2018 Spectrum Pharmaceuticals Provides Poziotinib Update
Dec 6, 2018 Spectrum Pharmaceuticals Announces Results from the RECOVER Phase 3 Study of ROLONTIS® (eflapegrastim) at the 2018 SABCS Annual Meeting
Dec 3, 2018 Spectrum Pharmaceuticals Announces Positive Results from Phase 2 Trial Evaluating Use of Oral Leucovorin to Potentially Mitigate Mucositis in Patients Treated with FOLOTYN® (pralatrexate)
Nov 30, 2018 Spectrum Pharmaceuticals Highlights Three Posters at the 60th Annual Meeting of the American Society of Hematology
Nov 13, 2018 Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors
Nov 8, 2018 Spectrum Pharmaceuticals Reports Third Quarter 2018 Pipeline Update and Financial Results
Nov 7, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 London Healthcare Conference on November 14
Nov 1, 2018 Spectrum Pharmaceuticals Announces Third Quarter 2018 Financial Results Teleconference and Webcast
Oct 23, 2018 Spectrum Pharmaceuticals Receives FDA Approval of KHAPZORY™ (levoleucovorin) for injection
Oct 18, 2018 Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer
Sep 27, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the 2018 Cantor Global Healthcare Conference on October 2
Sep 24, 2018 Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
Sep 12, 2018 Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient
Sep 5, 2018 Spectrum Pharmaceuticals Announces Release of Poziotinib Abstract as Part of the IASLC 19th World Conference on Lung Cancer
Aug 30, 2018 Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Aug 9, 2018 Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update
Aug 2, 2018 Spectrum Pharmaceuticals Announces Second Quarter 2018 Financial Results Teleconference and Webcast
Jun 29, 2018 Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint
Jun 25, 2018 Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)
May 30, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th
May 16, 2018 CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
May 9, 2018 Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th
Displaying records 1 - 25 of 766